Navigating the complex role of BAP1 in clear cell renal cell carcinoma
Year: 2026
Type: article
Study design: Systematic Review
Abstract: The BRCA1-associated protein 1 (BAP1) gene mutation defines a subtype of aggressive clear cell renal cell carcinoma (ccRCC) with distinct molecular phenotypes and poor prognosis. In-depth analysis of its regulatory role as a key tumor suppressor in multi-dimensional biological processes may help lay the groundwork for future precision treatment strategies, although their clinical implementation remains investigational. This review systematically summarizes the core functions of BAP1 in epigenetic regulation, DNA damage repair, remodeling of the immune microenvironment, and metabolic reprogramming. It also focuses on explaining the specific therapeutic vulnerabilities induced by BAP1 deficiency, including the synthetic lethal effect mediated by PARP inhibitors, the sensitivity of epigenetic targets such as EZH2/HDAC, and the synergistic mechanism of immune checkpoint inhibitors. The literature search was conducted based on the PubMed/Medline database, using keywords such as “BAP1”, “ccRCC”, “synthetic lethality”, “immunotherapy” for systematic screening and integrated analysis. BAP1-mutant ccRCC has become an important paradigm in precision oncology research. Currently, single-agent targeted or immunotherapy has shown initial efficacy, but the problem of drug resistance is prominent. Future therapeutic advances will depend on rationally designed combination regimens; whether biomarker-guided patient stratification can inform such regimens awaits prospective clinical validation.
Source: Discover Oncology
Authors: Xiaoxiang Gong, Likang Chen, Xia Wu
Institution: Second Xiangya Hospital of Central South University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: BAP1, clear cell renal cell carcinoma, tumor suppressor, epigenetic regulation, DNA repair, tumor immune microenvironment, metabolic reprogramming, synthetic lethality, PARP inhibitors, EZH2, histone deacetylase, immune checkpoint inhibitors, drug resistance, precision oncology, BAP1 mutation
Open Access status: gold
Estimated APC paid: $1,690
OpenAlex ID: W7225984967
